Clinical Trial Update: SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for SC10914 monotherapy in metastatic castration-resistant prostate cancer with g/s BRCA mutation, covering Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• SC10914

Snippet

Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 1, Phase 2 | Status: UNKNOWN